Brief: Xencor Doses First Subject In Phase 1/2 Study Of Xmab®942 In Development For Patients With Inflammatory Bowel Disease
04/11/2024 15:30
Nov 4 (Reuters) - Xencor Inc XNCR.O :
* XENCOR DOSES FIRST SUBJECT IN PHASE 1/2 STUDY OF XMAB®942
IN
DEVELOPMENT FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE
* XENCOR: CONTINUES TO EXPECT INITIAL DATA FROM ONGOING
STUDY
DURING H1 OF 2025
Source text: ID:nBw7xwXh6a
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates